Reviewing public plan prescription drug expenditures

eAwazMedicine

Ottawa – The latest edition of the Patented Medicine Prices Review Board (PMPRB) CompassRx report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000. CompassRx is an annual report published under the National Prescription Drug Utilization Information System (NPDUIS) research initiative. CompassRx provides insight into the factors driving prescription …

Assessing fetal alcohol spectrum disorder in Canada

eAwazMedicine

The assessment will help identify challenges and opportunities to strengthen Canada’s approach to addressing FASD Ottawa – Fetal alcohol spectrum disorder (FASD) is a lifelong disability caused by prenatal alcohol exposure that can affect both brain and body development. FASD is a serious public health issue linked to many complex social determinants of health. It can have far reaching impacts …

BRUIN Phase 1/2 Study of Pirtobrutinib Presented at 2023 ASH Annual Meeting

eAwazMedicine

INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell malignancies. These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, continue to …

Lilly’s Zepbound (tirzepatide) got additional 6.7% weight loss 

eAwazMedicine

INDIANAPOLIS – Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in The Journal of the American Medical Association (JAMA). Zepbound met the primary endpoint of mean percent change in body weight, and all key secondary endpoints …

Deal reached on retaining Medicago’s strategic R&D assets in Canada 

eAwazMedicine

Government of Canada also announces that Aramis Biotechnologies secured the assets needed to maintain, improve and expand Medicago’s plant-based technology platform in Canada that will enhance pandemic preparedness capabilities Québec – Following the cessation of Medicago’s operations by its parent company Mitsubishi Chemical Group Corporation (“MCG”) in February 2023, the Government of Canada’s objectives were threefold: maintain Medicago’s intellectual property …

WHO releases guidelines on chronic low back pain, cures

eAwazMedicine

Geneva – The World Health Organization (WHO) is releasing its first-ever guidelines on managing chronic low back pain (LBP) in primary and community care settings, listing interventions for health workers to use and also to not use during routine care. Low back pain is the leading cause of disability globally. In 2020, approximately 1 in 13 people, equating to 619 …

LITFULO Receives Health Canada Approval

eAwazMedicine

KIRKLAND, QC, December 4, 2023 – Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for LITFULO™ (ritlecitinib). A once-daily oral treatment, LITFULO is the first and only treatment approved by Health Canada for individuals 12 years of age and older with severe alopecia areata.[i] Approximately two per cent of the global population are affected …

Protect your child with routine vaccination

eAwazMedicine

Ottawa – You want to protect your child by keeping them safe and healthy. Childhood vaccinations can help you do that. Routine vaccinations have been around for decades and are safe and proven to help protect against vaccine-preventable diseases. We’ve got the facts to help you make an informed decision. Your child will need to be vaccinated at different times …

Update on CRYSTALIZE evidence trials

eAwazMedicine

London – AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (sodium zirconium cyclosilicate). The decision was made due to substantially increased enrolment timelines and low event rates, respectively, which made it prohibitive to deliver study results within a timeframe to meaningfully advance clinical practice. STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence …

Herbal treatment takes lives of HIV patients in Nigeria

eAwazMedicine

Geneva – The Network of People Living with HIV and AIDS in Nigeria, NEPWHAN, in Gombe State, said four of its members had died as a result of supposedly utilising herbal HIV medication. Muhammad Ibrahim, the association’s Programme Officer, revealed this in Gombe during an event commemorating World AIDS Day 2023. He said: “A lot of our members are subscribing …